Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).

被引：0
|
作者：
Haro-Silerio, Jaime Ivan [1 ]
Johns, Andrew [2 ]
Moussa, Mohammad Jad
Wang, Mindy
Wang, Emily
Kovitz, Craig A.
Campbell, Matthew T.
Jonasch, Eric
Shah, Amishi Yogesh
Tannir, Nizar M.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 261-492-2769; 261-137; 4; 2; 3615; 171; 137; 3; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.433
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：433 / 433
页数：1
相关论文
共 50 条
  • [1] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [2] Characteristics of patients with advanced renal cell carcinoma (aRCC) who received first-line (1L) nivolumab plus cabozantinib (NIVO plus CABO), pembrolizumab plus lenvatinib (PEM plus LEN), or nivolumab (NIVO) monotherapy in the real-world (RW) setting
    Zarrabi, Kevin K.
    Miron, Benjamin
    Yin, Xin
    Rosenblatt, Lisa
    Guttenplan, Sarah B.
    John, William
    Miller, Taavy A.
    Asgarisabet, Parisa
    Pathak, Prathamesh
    Ahlquist, Monica
    Gash, Yul Brian
    Geynisman, Daniel M.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [3] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
  • [5] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
  • [6] Efficacy outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
    McGregor, Bradley Alexander
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Rodriguez, Cristina Suarez
    Bourlon, Maria Teresa
    Barata, Pedro C.
    Gulati, Shuchi
    Stwalley, Brian
    Del Tejo, Viviana
    Du, Ella X.
    Wu, Aozhou
    Chin, Andi
    Betts, Keith A.
    Huo, Stephen
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari David
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Okusaka, Takuji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma
    Hindie, Elif
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03): : 287 - 287
  • [9] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
  • [10] Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
    Santoni, Matteo
    Rizzo, Alessandro
    Mollica, Veronica
    Rosellini, Matteo
    Marchetti, Andrea
    Fragomeno, Benedetta
    Battelli, Nicola
    Massari, Francesco
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 45 - 51
12345